Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
largest decrease » larger decrease (Expand Search), marked decrease (Expand Search)
threat decrease » greater decrease (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
largest decrease » larger decrease (Expand Search), marked decrease (Expand Search)
threat decrease » greater decrease (Expand Search)
-
2061
Combination therapy exhibited apoptosis in Ba/F3 EML4-ALKmutant cell models.
Published 2025Subjects: -
2062
-
2063
The characteristics of patient groups were used to prove the method’s applicability.
Published 2025Subjects: -
2064
-
2065
-
2066
-
2067
ROS, K<sup>+</sup> efflux and cathepsin B are required for NLRP3 activation.
Published 2025Subjects: -
2068
-
2069
-
2070
-
2071
Differences in health-related quality of life indexes after disease onset between groups.
Published 2025Subjects: -
2072
Changes in subcutaneous fat thickness and muscle mass (Approximately here).
Published 2025Subjects: -
2073
-
2074
-
2075
Ba/F3 EML4-ALK<sup>mutants</sup> exhibit variable dose-response to ABT-199 treatment.
Published 2025Subjects: -
2076
-
2077
-
2078
-
2079
-
2080